Incidence and Prevalence

Global Diabetes Estimates: Incidence and Prevalence

Current Global Prevalence

As of 2021, there were 529 million people living with diabetes worldwide, with a global age-standardized total diabetes prevalence of 6.1%. The diabetes landscape is dominated by Type 2 diabetes, which accounts for 96.0% of all diabetes cases and 95.4% of diabetes disability-adjusted life years (DALYs) globally.

The prevalence of diabetes continues to increase worldwide, making diabetes-related macrovascular morbidity and mortality major health care problems.

Regional Variations

The highest age-standardized rates in 2021 were observed in: - North Africa and the Middle East: 9.3% - Oceania region: 12.3%

Qatar had the world's highest age-specific prevalence of diabetes at 76.1% in individuals aged 75-79 years.

Ethnic and Geographic Disparities

Significant ethnic variations in diabetes prevalence were observed in Australia (2021 data): - Overall Australian prevalence: 6.3% - East Asian ancestry: ranged from 4.2% (Japanese) to 12.6% (Filipino) - South/Central Asian ancestry: ranged from 7.3% (Armenian) to 18.4% (Bangladeshi) - Middle Eastern/North African ancestry: ranged from 5.4% (Jewish) to 12.3% (Iraqi) - Oceania: Australian Aboriginal (17.5%), Fijian (12.3%), Maori (10.0%), Samoan (16.3%), and Tongan (17.4%)

In Asian countries, there is considerable geographical variation in diabetes prevalence, with three factors independently associated with prevalence: hypertension prevalence, obesity prevalence, and quality of healthcare governance.

Country-Specific Data

• United States: As of 2021, 38.4 million Americans have diabetes. This represents a significant increase from 2011, when an estimated 26 million persons aged ≥20 years (11.3% of the U.S. population) had diabetes.
• Republic of Srpska (Bosnia and Herzegovina): The average incidence of diabetes in the period 2017-2022 was 19/100,000, with the highest incidence of 28.7/100,000 in 2020.
• Mozambique: The prevalence of diabetes was 7.4% in 2014/2015, representing a more than twofold increase from 2005 (2.9%).
• China (Guizhou province): The standardized prevalence of diabetes was 6.01% in urban residents and 3.47% in rural residents.
• England: Diabetes prevalence increased from 3.74% to 7.25% in men and from 2.28% to 4.88% in women between 1994-2006.

Risk Factors and Projections

In 2021, 52.2% of global type 2 diabetes DALYs were attributable to high BMI, with the contribution of high BMI to type 2 diabetes DALYs rising by 24.3% worldwide between 1990 and 2021.

By 2050, more than 1.31 billion people are projected to have diabetes globally. Projected age-standardized total diabetes prevalence rates by 2050 will exceed 10% in: - North Africa and the Middle East: 16.8% - Latin America and Caribbean: 11.3%

By 2050, 89 (43.6%) of 204 countries and territories will have an age-standardized rate greater than 10%.

Diabetes Mellitus is among the top ten leading causes of mortality globally and is projected to rank seventh by 2030.

Company drugs in pipeline

Biocon Biologics' Pipeline Indications

I notice that the provided context doesn't contain specific information about Biocon Biologics' pipeline indications. Without this information, I cannot provide details about which therapeutic areas and disease indications Biocon Biologics currently has drugs in development for, or the clinical trial stages of their pipeline drugs.

To properly answer this question would require information about:

• Current development programs at Biocon Biologics
• Therapeutic areas they focus on
• Disease indications targeted by their pipeline drugs
• Clinical trial stages of various candidates
• Regulatory status of their development programs

For accurate information about Biocon Biologics' current pipeline, I would recommend consulting their official website, recent investor presentations, or pharmaceutical industry databases that track development programs.